These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 10535525

  • 1. Urinary zinc excretion and zinc status of patients with beta-thalassemia major.
    Aydinok Y, Coker C, Kavakli K, Polat A, Nisli G, Cetiner N, Kantar M, Cetingül N.
    Biol Trace Elem Res; 1999 Nov; 70(2):165-72. PubMed ID: 10535525
    [Abstract] [Full Text] [Related]

  • 2. Renal tubular function in children with beta-thalassemia minor.
    Kalman S, Atay AA, Sakallioglu O, Ozgürtaş T, Gök F, Kurt I, Kürekçi AE, Ozcan O, Gökçay E.
    Nephrology (Carlton); 2005 Oct; 10(5):427-9. PubMed ID: 16221088
    [Abstract] [Full Text] [Related]

  • 3. The effects of chelators on zinc levels in patients with thalassemia major.
    Erdoğan E, Canatan D, Ormeci AR, Vural H, Aylak F.
    J Trace Elem Med Biol; 2013 Apr; 27(2):109-11. PubMed ID: 23164519
    [Abstract] [Full Text] [Related]

  • 4. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP, Kumar S, Choudhury P, Talukdar B, Puri RK.
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Renal tubular dysfunction in pediatric patients with beta-thalassemia major.
    Ahmadzadeh A, Jalali A, Assar S, Khalilian H, Zandian K, Pedram M.
    Saudi J Kidney Dis Transpl; 2011 May; 22(3):497-500. PubMed ID: 21566307
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Intensification of chelating-therapy in patients with thalassemia major.
    Laws HJ, Göbel U, Christaras A, Janssen G.
    Klin Padiatr; 2005 May; 217(3):120-5. PubMed ID: 15858702
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Continuous desferrioxamine infusion by an infusor in thalassaemia major.
    Canatan D, Temimhan N, Dinçer N, Ozsancak A, Oğuz N, Temimhan M.
    Acta Paediatr; 1999 May; 88(5):550-2. PubMed ID: 10426179
    [Abstract] [Full Text] [Related]

  • 19. Phase Ib clinical trial of starch-conjugated deferoxamine (40SD02): a novel long-acting iron chelator.
    Harmatz P, Grady RW, Dragsten P, Vichinsky E, Giardina P, Madden J, Jeng M, Miller B, Hanson G, Hedlund B.
    Br J Haematol; 2007 Aug; 138(3):374-81. PubMed ID: 17614825
    [Abstract] [Full Text] [Related]

  • 20. [Therapeuetic management of patients with thalassemia major].
    Thuret I.
    Bull Soc Pathol Exot; 2001 May; 94(2):95-7. PubMed ID: 11475036
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.